Aktienanalyse zu CytomX Therapeutics Inc (CTMX)CTMXCytomX Therapeutics Inc

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

CytomX Therapeutics Inc is currently trading at $3.21, with a significant recent decline in revenue of 92.4% year-over-year reported in Q2. Despite receiving FDA Fast Track Designation for its lead candidate Varseta-M, the company faces challenges with profitability and cash reserves, which decreased from $346.7M to $330.3M. The RSI is at 37.147, indicating potential oversold conditions, but the overall financial health remains concerning. Therefore, while there are potential catalysts, the risks outweigh the current buying opportunity, suggesting a hold position.

7 analysts cover CTMX: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 9.00.